4 results
Primary: To evaluate the safety and tolerability of RO5185426 inpatients with metastatic melanoma (Stage IV; AJCC) harboringthe BRAF V600 mutationSecondary: To evaluate the efficacy of RO5185426 as objectiveresponse rates (ORRs) determined by the…
The primary objective of this trial is to evaluate the efficacy of vemurafenib using BestOverall Response Rate (BORR), as assessed by an Independent Review Committee (IRC)using RECIST, v1.1 criteria in the brain of metastatic melanoma patients with…
The primary objective of this study is to provide continued access to vemurafenib for eligible patients with BRAFV600 mutation-positive malignancy who were previously treated in an antecedent vemurafenib protocol and did not meet the protocol*s…
The primary objective of this study is to investigate local and systemic effects of BAY 1007626 on:- Number of bleeding and spotting days,- Endometrial histology,- Ovulation (as surrogate for systemic effects).The secondary objective of this study…